A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Dutasteride (Primary) ; Enzalutamide (Primary) ; Finasteride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Results assessing safety and efficacy of enzalutamide (Enz) with 5-alpha reductase inhibitors as an androgen deprivation therapy sparing approach for older men with castration-sensitive prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 28 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2023 Planned End Date changed from 1 Sep 2024 to 1 Oct 2023.